Home>Products
product presentation
Adhering to the "medical service provider," Green Cross insists on contributing to the medical and health industry with excellent medicines and excellent services.
The main raw materials of Green Cross products are selected from the world's best Japanese Ajinomoto and Japan Union; the quality standards of internal control are higher than the national standards; the management mode of Japanese pharmaceutical companies follows the aspects of production technology, facilities and equipment, product quality, and personnel training. In 2018, Green Cross's parenteral nutrition-related products were selected as national safety re-evaluation standard preparations and became leaders in the field of parenteral nutrition treatment in China.
Amino acid injection in 1993 and production of fat emulsion injection in 1996
In 1997 passed the national GMP certification
Luan was approved as a Guangzhou branded product by the Guangzhou Municipal Government
The change process of fat emulsion injection (C14~24) and improvement of drug quality standards were approved by the State Administration of Food and Drug Administration (CFDA) and issued an approval document.
Green Cross Infusion Products as a successful reference for domestic real estate products as a reference preparation
treatment of disease

China is the largest country in the world for diabetics. According to IDF statistics, the number of patients in China in 2015 was as high as 109.6 million people, and 1.3 million people died each year from diabetes and its complications. Without intervention, the number of patients in China will rise to 154 million in 2040. Even with an estimated treatment cost of 2 yuan per person per day, the cost of diabetes treatment has exceeded 100 billion. China is the largest country in the world for diabetics. According to IDF statistics, the number of patients in China in 2015 was as high as 109.6 million people, and 1.3 million people died each year from diabetes and its complications. Without intervention, the number of patients in China will rise to 154 million in 2040. Even with an estimated treatment cost of 2 yuan per person per day, the cost of diabetes treatment has exceeded 100 billion. China is the largest country in the world for diabetics. According to IDF statistics, the number of patients in China in 2015 was as high as 109.6 million people, and 1.3 million people died each year from diabetes and its complications. Without intervention, the number of patients in China will rise to 154 million in 2040. Even with an estimated treatment cost of 2 yuan per person per day, the cost of diabetes treatment has exceeded 100 billion.

Parkinson’s disease (PD) is a common degenerative disease of the nervous system. It is common in the elderly. The average age of onset is about 60 years old. Parkinson’s disease is less common in young people below 40 years of age. The prevalence of PD in people over 65 years old in China is about 1.7%. Most Parkinson's disease patients are sporadic cases, and less than 10% of patients have a family history. The main pathological change of Parkinson's disease is degeneration of dopamine (DA) neurons in the midbrain substantia nigra, which causes a significant decrease in the DA content of the striatum and causes the disease. The exact cause of this pathological change is still unclear. Genetic factors, environmental factors, aging, and oxidative stress may all be involved in the degenerative death of PD dopaminergic neurons.


In 1817 the British doctor James Parkinson first described the disease in detail, its clinical manifestations mainly include resting tremors, bradykinesia, myotonia and posture gait disorders, and patients may be associated with non-exercise such as depression, constipation and sleep disorders symptom. The diagnosis of Parkinson's disease mainly depends on medical history, clinical symptoms and signs. There are no abnormal changes in the general auxiliary inspection. Drug therapy is the main treatment for Parkinson's disease. Levodopa preparations are still the most effective drugs. Surgical treatment is an effective supplement to medical treatment. Rehabilitation, psychotherapy and good care can also improve symptoms to a certain extent. Although the currently used therapeutic methods can only improve the symptoms, can not prevent the progression of the disease, and can not cure the disease, effective treatment can significantly improve the quality of life of patients. Life expectancy of patients with PD is not significantly different from that of the general population.

Alzheimer's disease (AD) is a progressive and progressive neurodegenerative disorder that is occult onset. Clinical manifestations are characterized by comprehensive manifestations of dementia such as memory disorders, aphasia, apraxia, misstatement, impairment of visual space skills, executive dysfunction, and changes in personality and behavior, and the etiology has not been known. Those who develop before the age of 65 are called Alzheimer's dementia; those who are older than 65 are called Alzheimer's dementia.


Most epidemiological studies suggest that family history is a risk factor for the disease. In some patients, members of the family members who suffer from the same disease are higher than the general population. In addition, it is also found that the risk of congenital malady increases. Further genetic studies confirmed that the disease may be caused by an autosomal dominant gene. Recently, through gene mapping studies, the pathological gene for amyloid in the brain was found on the 21st pair of chromosomes. It can be seen that dementia is more related to heredity.

Guangzhou Green Cross Pharmaceutical Co., Ltd. All rights reserved
Address: No. 2, Jiaoyuan Road, Economic Development Zone, Guangzhou Tel: 020-37209210, 020-37887419
Internet Drug Information Service Qualification Certificate No.: (Guangdong) Non-operating one 2018—0063 : 粤ICP备18027417号-1